HER2 inhibition: From discovery to clinical practice

被引：41
作者：
Chang, Jenny C. [1 ]
机构：
[1] Baylor Coll Med, Breast Ctr, Houston, TX 77030 USA
来源：
CLINICAL CANCER RESEARCH | 2007年 / 13卷 / 01期
关键词：
D O I：
10.1158/1078-0432.CCR-06-2405
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1 / 3
页数：3
相关论文
共 50 条
  • [41] From HER2 FISH to DISH
    Alabdulghani, R.
    Done, S.
    Youngson, B.
    Miller, N.
    Berman, H.
    Mulligan, A. M.
    Torlakovic, E.
    Craddock, K.
    LABORATORY INVESTIGATION, 2014, 94 : 517A - 517A
  • [42] From HER2 FISH to DISH
    Alabdulghani, R.
    Done, S.
    Youngson, B.
    Miller, N.
    Berman, H.
    Mulligan, A. M.
    Torlakovic, E.
    Craddock, K.
    MODERN PATHOLOGY, 2014, 27 : 517A - 517A
  • [43] Predicting HER2 scores from registered HER2 and H&E images
    Tavolara, Thomas E.
    Niazi, M. Khalid Khan
    Tozbikian, Gary
    Wesolowski, Robert
    Gurcan, Metin N.
    MEDICAL IMAGING 2022: DIGITAL AND COMPUTATIONAL PATHOLOGY, 2022, 12039
  • [44] HER2 testing: Insights from pathologists' perspective on challenging HER2 cases.
    Grimm, Erin V.
    Swenson, Karen K.
    Krueger, Janet
    Hicks, David G.
    Allison, Kimberly H.
    Yaziji, Hadi
    Rendi, Mara Hester
    Susnik, Barbara
    Downs-Kelly, Erinn
    Tsai, Michaela L.
    Lillemoe, Tamera J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [45] HER2 Gene Protein Assay Is Useful to Determine HER2 Status and Evaluate HER2 Heterogeneity in HER2 Equivocal Breast Cancer
    Hou, Yanjun
    Nitta, Hiroaki
    Li, Zaibo
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2017, 147 (01) : 89 - 95
  • [46] Evaluation of analytical accuracy of HER2 status in patients with breast cancer Comparison of HER2 GPA with HER2 IHC and HER2 FISH
    Jensen, Steffen Grann
    Thomas, Peter Engel
    Christensen, Ib Jarle
    Balslev, Eva
    Hansen, Alastair
    Hogdall, Estrid
    APMIS, 2020, 128 (11) : 573 - 582
  • [47] Genomic and clinical characterization of breast tumors with unusual HER2 FISH pattern (ratio < 2, HER2 copy number ≥ 6): Are they mostly HER2 "positive?"
    Wei, Christina H.
    Yang, Lixin
    Stewart, Daphne
    Bedell, Victoria
    Schmolze, Daniel
    Apple, Sophia
    Murata-Collins, Joyce L.
    Pillai, Raju
    Mortimer, Joanne E.
    CANCER RESEARCH, 2022, 82 (04)
  • [48] HER2 positive gastric cancer: Who benefits from HER2 targeted therapy?
    Kolbe, K.
    Haffner, I.
    Schierle, K.
    Maier, D.
    Geier, B.
    Luber, B.
    Kretzschmar, A.
    von Weikersthal, Fischer L.
    Ahlborn, M.
    Riera, J.
    Rau, B.
    Siegler, G.
    Fuxius, S.
    Decker, T.
    Wittekind, C.
    Lordick, F.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 156 - 157
  • [49] Dual HER2 inhibition and paclitaxel in metastatic breast cancer
    Brower, Vicki
    LANCET ONCOLOGY, 2015, 16 (02) : E57 - E57
  • [50] "Vertical" Inhibition of HER2 Yields Horizontal Gains in the Clinic
    Sledge, George W.
    Pegram, Mark D.
    CLINICAL CANCER RESEARCH, 2015, 21 (12) : 2663 - 2665
12345